The anti-tumor effect of vitamin D has been well recognized but its translational application is hindered by side effects induced by supra-physiological concentration of vitamin D required for cancer treatment. Thus, exploring the vitamin D tumor suppressive functional mechanism can facilitate improvement of its clinical application.

A team of researchers from the University of Rochester and the University of Tainan, Taiwan used to screen miRNA profiles in response to vitamin D and found that a tumor suppressive miRNA, miR-98, is transcriptionally induced by 1α,25-dihydroxyvitamin (1,25-VD) in LNCaP. Mechanistic dissection revealed that 1,25-VD-induced miR-98 is mediated through both a direct mechanism, enhancing the VDR binding response element in the promoter region of miR-98, and an indirect mechanism, down-regulating LIN-28 expression. Knockdown of miR-98 led to a reduction of 1,25-VD anti-growth effect and overexpression of miR-98 suppressed the LNCaP cells growth via inducing G2/M arrest. And CCNJ, a protein controlling cell mitosis, is down-regulated by miR-98 via targeting 3′-untranslated region of CCNJ. Interestingly, miR-98 levels in blood are increased upon 1,25-VD treatment in mice suggesting the biomarker potential of miR-98 in predicting 1,25-VD response.

Biomarker potential of miRNAs relies on their high stability and existence in formalin-fixed tissue, cell free serum/plasma, and urine. The biological response to vitamin D varied among individuals. Factors contributing to a broad range of sensitivity to vitamin D include genomic polymorphisms of VDR and metabolism enzymes and pathological conditions altering VDR activity.

Biomarkers representing biological response of vitamin D treatment will be more meaningful than measurement of serum vitamin D level due to a broad range of sensitivity to vitamin D and other factors. Therefore the research team explored the biomarker potential of miR-98 representing vitamin D treatment in mice bearing prostate cancer. The cellular fraction of blood contains miR-98 whose expression correlated well with vitamin D treatment in both wild type and cancerous mice. Further investigation correlating expression levels of miR-98 and other vitamin D-regulated anti-tumor miRNAs (such as miR-22) in blood or other body fluid with anti-tumor effect of vitamin D is demanded.

Together, the finding that growth inhibitive miR-98 is induced by 1,25-VD provides a potential therapeutic target for prostate cancer and a potential biomarker for 1,25-VD anti-tumor action.


Related Service

miRNA Microarray Service – LC Sciences provides a microRNA (miRNA) expression profiling service using microarrays based on our in-house developed µParaflo® technology platform. We have standard arrays for all mature miRNAs of all species available in the latest version of the miRBase database (Release 21, July 2014). Our service is comprehensive and includes sample labeling, array hybridization, image data processing and in-depth data analysis. Two-three weeks after receiving your total RNA samples, we’ll send you both the raw and fully analyzed data. [Learn more…]


Reference

Ting HJ, Messing J, Yasmin-Karim S, Lee YF. (2013) Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin. J Biol Chem 288(1), 1-9. . [abstract]


Identifying the molecular mechanisms behind carcinogenic potential in lung cancers Developing non-invasive tests for prostate cancer